Summary: Two biotin-avidin based enzyme immunoassays were developed using three monoclonal anti-CEA antibodies with distinct epitope-and antigen-specificities. A broadly cross-reactive monoclonal anti-CEA antibody (T84.1) was immobilized on a solid support. Either monoclonal antibody T84.66 or CEA. 11 was used äs the second, biotin-labeled monoclonal antibody. Both antibodies do not cross-react with normal granulocytes or bile canaliculi. Monoclonal antibody CEA. 11 binds to CEA and to an antigen with a relative rnolecular mass of 128000 present in extracts from solid carcinomas. Monoclonal antibody T84.66 does not cross-react with the antigen of 128000. After adsorption of tumour extracts to a CEA-specific immunosorbent, residual activity was measurable by the CEA. 11 assay, but not by the T84.66 assay. Serum samples (n = 726) from patients with malignant and non-malignant disease, äs well äs from healthy volunteers, were analysed by both immunoassays and by two commercial CEA immunoassays. In comparison with the T84.66 assay and the cpmmercial assays, the CEA. 11 assay did not significantly increase the sensitivity or specificity of tumour diagnosis.
Introduction
^ genes: ^ ?ene encoding CEA (2j 3), the non-specific The carcinoembryonic antigen (CEA) is a marker of cross-reacting antigen (NCA) (4, 5) , and the biliary human colorectal carcinomas, CEA is a well defined glycoprotein I (6, 7) . According to a recent study, the glycoprotein with a relative molecular mass (M r ) of primary transcript of the biliary glycoprotein I gene 180000 (for review see I.e. (1) ). Antibodies induced is modified by alternative splicing (7) . This finding against CEA may cross-react with a variety of anti-suggests the existence of several biliary glycoprotein gens present in normal and cancerous tissues, body I-related antigens. Our own data indicate that normal fluids, effusions, and faeces. As shown recently, these plasma contains two different biliary glycoprotein Iantigens are the products of at least three distinct related antigens (8, 9) .
In previous studies, we described five monoclonal antibodies against CEA which bind to different epitopes of the antigen (10) (11) (12) . Two of these antibodies preferentially bind to tumour tissues (10, 13) . The antigen specificities of both antibodies are distinct. One monoclonal antibody (CEA. 11), in addition to CEA, binds a tumour-associated antigen with a relative molecular mass of 128000. The second monoclonal antibody (T84.66) does not cross-react with the latter antigen (14) . This antigen may be similar to or identical with CEAi ow described by Hammerström and co-workers (15) . Since it is not yet established whether the CEA-related antigen of M T 128000 is a product of an äs yet undescribed member of the CEA gene family, whether it is a product of alternatively spliced mRNA, or whether it is generated by posttranslational modifications, the antigen will be designated "CEA-related antigen of M T 128000 (CRA-128)".
Despite of the fact that the nature of CRA-128 is not firmly established, the antigen specificity of monoclonal antibody CEA. 11 has been confirmed by other investigators (16, 17) . Suzuki et al. (16) described an immunoassay which measured an antigen similar to CRA-128 in addition to CEA. In some serum specimens from tumour patients, significantly elevated antigen concentrations remained after adsorption to a CEA-specific immunadsorbent. However, no Information on the relative frequency of such specimens among sera from tumour patients was given.
Since CRA-128 occurs in a high percentage of tumour tissues (unpublished observation), we addressed the questions of whether the serum determination of CEA + CRA-128 can increase the diagnostic sensitivity of tumour diagnosis and whether CRA-128 may be associated with tumours at certain sites.
Materials and Methods

Monoclonal antibodies and CEA Standard
The monoclonal anti-CEA antibodies were induced, characterized and purified äs described (10, 11) . The monoclonal antihepatitis B surface (Hbs) antigen antibody was kindly donated by Hoffmann-La Röche, Basel, Switzerland. All monoclonal antibodies used in this study were of subclass Igd. The CEA Standard preparation, which was purified according to Priichard & Todd (18) , was supplied by Dr. Shively, Beckman Research Institute of the City of Hope, Duarte, CA, U. S. A.
Biotinylation procedure
Monoclonal antibodies were biotin-labelled äs described (19, 20) . As antibodies, the monoclonal antibodies T84.66 and CEA. 11 were used. Molar ratios of N-hydrosuccinimidobiotin (M r = 341.4) to IgG (M r = 150000) in the ränge of 10-600 were tested, in order to find which ratio yields the highest sensitivity in the solid phase EIA. Using monoclonal antibody T84.66, a ratio of 60-70 was found to be optimal. This ratio was also adopted for monoclonal antibody CEA. 11.
Preparation of F(ab) 2 -fragments
The IgGj fraction of monoclonal antibody T84.1 was purified from ascitic fluid over protein^A sepharose (21) . IgGj (6-12 g/l) was digested with pepsin äs described (22) . The cleavage products were characterized by gel permeation HPLC (TSK 3000, LKB, Gräfelfing, F. R. Genhany) and SDS-PAGE under reducing and nön-reducing conditions.
CEA-immunoassays
Polystyrene beads were coated with the Igd fraction or F(ab)2-fragments of monoclonal antibody T84.1. Per 100 beads, 30 ml of a 20 mmol/1 sodium acetate buffer, pH 5.5, containing 10 mg/1 of antibody IgG ör antibody fragiments, respectively, was used. Coating was performed overnight at room temperature. Blocking pf unspecific binding sites and storage of the beads was performed in phosphate buffered saline containing 20 mg/1 bovine serum albumin, The CEA Standard was dissolved in phosphate buffered saline containing 10 mg/1 bovine serum albumin. Either monoclonal antibody T84.66 or CEA. 11 was used äs the second biotin-labelled antibody, The antibodies were dissolved in 0.1 mol/1 potassium phosphate buffer, pH 7.3, containing foetal calf serum (200 ml/l), 9.2 ml/l Tween 20 and 30 ml/l normal mouse serum. The final concentratiön of biotinlabelled monoclonal antibody T84.66 was 2.7 mg/1. A final concentration of 5.7 mg/1 was used for F(ab) 2 -fragments from monoclonal antibody CEA. 11.
Sample tubes contained the following Solutions (voluöies in brackets): serum (100 ); phosphate buffered saline/bovine serum albumin (50 ); Solutions of biotinylated monoclonal antibodies (50 ). Standard tiibes were prepared äs foliows: normal seriim from a serum pool with a CEA^-concentration of < l g/l (100 ); CEA-standard in phosphate buffered saline/ bovine serum albumin (50 ); Solutions of biotinylated monoclonal antibodies (50 ). Subsequently, immobilized monoclonal antibody T84.1 was added. For the T84.66 EIA, undigested IgGt was used. The incübation time was l h (37 °C). For the CEA. 11 EIA, immobilized F(ab) 2 -fragments from monoĉ lorial antibody T84.1 were incubated for 17 h at room temperature. After the appropriate incübation time, the beads were washed 3 times with 0.1 mol/1 potassium phosphate buffer, pH 7.3. Subsequently, 200 of avidin-peroxidase conjugate (Sigma, Taufkirchen, F. R. Germany) diluted in 0.2 mol/1 potassium phosphate buffer, pH 6.5, containing 200 ml/1 biotinf ree foetal calf serum, was added. The concentration of avidinperoxidase conjugate was chosen äs the highest concentration yielding negligible unspecific binding. After 30 min at room temperature, the beads were washed 3 times in 0.1 mol/1 citrate buffer, pH 5.0, and 300 of Substrate solution containing 6 mmol hydrogen peroxide and 40 mmol o-phenylenediamine (Sigma) per litre of 0.1 mol/1 citrate buffer, pH 5.0, were added. After incübation for 30 min at room temperature in the dark, the reaction was stopped with 2 ml of a l mol/1 HCl-solution. The absorbance was detennined at 492 nm.
Immunoassays for anti-mouse IgG binding activity In these assays, antibody T84.1 was replaced by a monoclonal anti-HBs antibody om the solid phase. Antibody CEA. 11 or T84.66 was used äs the secoad antibody. With the exception of these modifications, the single incübation Step assays were performed äs in the original CEA assays.
Extraction of tissues and Western biot
The extraction of tumour tissues, immunosorbent purification, and Western blots were performed äs described (14) .
Commercial CEA-immunoassays Commercial CEA-immunoassays were obtained from HofTniann-La Röche, Basel, Switzerland, and from Abbott, Wiesbaden, F. R. Germany. The assays were performed according to the instructions of the manufacturers.
Serum specimens
CEA determinations were performed in 726 serum samples using four different immunoassays (2 assays developed in our laboratory, 2 coramercial assays). Serum samples were obtained from the following groups of persons or patients (number of samples in brackets):
Healthy blood donors, non-smokers (98); healthy blood donors, smokers (42); gastric cancer (21); pancreatic cancer (10); cervical cancer (13) (14); pancreatitis (13); non-malignant diseases of the gail bladder (9); non-malignant lung disease (51); non-malignant renal disease (60); other non-malignant conditions (32).
Statistical procedures
The following non-parametric tests were used: Spearman's coefficient of rank correlation, Kolmogorov-Smirnov test, and Wilcoxorfs matched pairs signed rank test.
Results
Establishment of immunoassays, elimination of anti-mouse IgG activity in sera
Two additive solid-phase enzyme immunoassays were established using three monoclonal anti-CEA antibodies with different epitope-and antigen-speeificities. For both immunoassays, the broadly cross-reactive, high affinity antibody T84.1 was adsorbed to a solid support. Either monoclonal antibody T84.66 or monoclonal antibody CEA. 11 was used äs the second antibody. For simplicity, the immunoassay with monoclonal antibody T84.66 äs seeond antibody will be designated "T84.66 assäy", and the immunoassay with monoclonal antibody CEA. 11 äs second antibody will be designated "CEA. 11 assay". In addition to the above immunoassays, an immunoassay for the detection of anti-mouse IgG binding activity in sera was developed. Instead of monoclonal antibody T84.1, a monoclonal anti-HBs antibody was immobilized on a solid support. Either monoclonal antibody CEA. 11 or T84.66 was used äs the second antibody. This immunoassay, in which no CEA-related antigens are measured, will be designated "interference assay". All immunoassays were based on the biotin-avidin System. Avidin-peroxidase conjugate was added to the biotin-labelled second antibody bound to the antigen. The colour reaction was developed with H 2 O 2 /o-phenylenediamine äs Substrate.
Initially, both the T84.66 and CEA. 11 immunoassay versions, were established with native IgGi of monoclonal antibody T84.1 adsorbed to the solid support. In both initial versions, normal mouse serum was not added. When normal sera were investigated by the initial Version of the CEA. 11 immunoassay, CEAvalues exceeding 10 g/l were occasionally observed. This effect was absent in the T84.66 immunoassay. A preliminary comparison of the CEA-concentrations determined by the T84.66 and CEA. 11 immunoassays with the values obtained from a commercial assay (Abbott) revealed significant differences in a serum sample from a patient who had received therapeutic doses of a murine monoclonal antibody.
In order to eliminate the unspecific interferences, serum specimens from the above patient and from an apparentiy healthy person were further analysed. After addition of 10 ml/l mouse serum (final concentration) to the T84.66 and CEA. 11 immunoassay, respectively, the CEA-concentrations in the patient's sample decreased to concentrations comparable with those measured in a commercial assay (tab. 1). The addition of normal mouse serum did not affect the elevated CEA level measured in the normal serum sample by the CEA. 11 immunoassay (tab. 1). The interfering serum samples were further analysed by an interference assay in which the anti-CEA monoclonal antibody adsorbed to the solid phase was replaced by a monoclonal antibody of identical subclass (IgGj) with a specificity unrelated to CEA. As shown in figure l, the normal serum interfered only after a prolonged incubation time, irrespective of which anti-CEA monoclonal antibody was used äs second antibody. In contrast, the response with tumour serum apprpached a maximum after an incubation time of only l h. The interfering effect of the normal serum in the CEA. 11 immunoassay could not be suppressed by the addition of non-immune mouse IgG at concentrations of up to l mg/reaction volume (not shown). In order to eliminate the unspecific interference of the normal serum in the CEA. 11 immunoassay, F(ab) 2 -fragments from monoclonal antibody T84.1 were prepared. As shown in table l, the measured CEA value decreased to 1.0 g/l when F(ab) 2 instead of native IgG fragments were adsorbed to the solid support. With the revised Version of the CEA. 11 immunoassay, CEA concentrations exceeding 10 were not observed in sera from healthy blood donors or in sera from healthy smokers.
Characterization of immunoassays
The characteristics of the final assay versions of the immunoassays (sensitivity, measuring r nge, recovery, precisiori) are shown in tabie 2. In dilution experiments, the dose-response curves of tunaour extracts ran parallel with the Standard cufVes (tab. 3).
Specificities of immunoassays
The specificities of the two immunoassays were characterized by the use of tumour extracts in which high amounts of the tumour-asspciated CEA variant of M τ 128000 could be demonstrated by Western blotS; Figure 2 sh ws a Western blot of an extract fr rn a primary rectal carcinoma el ted from a T84. exclusively binds to an antigen with a M r of only 177 000. According to M T and immunoreactivity, e. g., binding of each fo the five monoclonal anti-CEA antibodies with different epitope specificities, this antigen is probably identical with CEA. In addition to CEA, monoclonal antibody CEA. l1 binds an additional antigen with a M r of 128 000 (lane 2). Antigen concentrations were detennined in extracts from the rectal and from a gastric carcinoma prior to and after adsorption to a T84.66 immunosorbent. In both tüm-our extracts, the CEA concentrations determined by the CEA. 11 immunoassay were higher than those measured by the T84.66 immunoassay (tab. 4). After adsorption to a T84.66 immunosorbent, no CEA could be measured by the T84.66 immunoassay. In the CEA. 11 immunoassay, a significant CEA-activity remaiiied after immurioadsorption. Figure 3 gives a schematic presentation of the specificities of both immunoassays. Determination of CEA in serum samples CEA was detennined in a total of 726 serum samples from healthy persons and from patients with nonmalignant and malignant disease, using four different immunoassays. Table 5 The correlation of CEA-concentrations in serum samples from patients with malignant disease is demonstrated in figure 4 and table 6. The T84.66 immunoassay shows a good correlation with two commercial assays. The CEA. 11 immunoassay shows a lower correlation to the T84.66 assay and to the commercial assays. Figure 5 demonstrates the distributions of CEA concentrations in different malignant and non-malignant diseases. In colorectal cancer, the median of the CEA concentrations measured by the CEA. 11 assay is higher than the corresponding median of the T84.66 assay. This difference, however, is not statistically significant. In mammary cancer, the CEA-concentrations obtained by the T84.66 assay were significantly higher than the corresponding concentrations determined by the CEA. 11 assay. It is interesting to note that in the group of patients with non-malignant kidney disease, including a high percentage of patients with chronic renal failure, the CEA. 11 assay measured significantly higher concentrations than the T84.66 immunoassay. The discrimination by the T84.66 and CEA. 11 immunoassays between sera from normal persons and patients with non-malignant disease on the one hand and with malignant disease on the other hand were analysed by the Kolmogorov-Smirnov-test (flg. 6). When sera from patients with colorectal cancer are compared with sera from patients with non-malignant gastrointestinal and liver disease, a higher level of significance is obtained for the CEA. 11 assay than for the T84.66 assay. In contrast, the T84.66 assay shows a higher level of significance for carcinomas of the hing vs. benign lung disease and for mammary cancer vs. normal blood donors.
Discussion
Monoclonal anti-CEA antibodies bind to different human carcinomas such s colorectal, mammary, and lung carcinomas. According to their reactivity with normal tissues, two major subgroups can be distinguished. One subgro p is characterized by antibodybinding to normal granulocytes and/or bile canaliculi, whereas monoclonal antibodies of the second subgroup do not significantly cross-react with these normal tissues (11, 13) . In previous studies, we described five monoclonal anti-CEA antibodies which bind to different epitopes on CEA (10) (11) (12) . Three of these antibodies cross-re ct with gfanulocytes and/or bile canaliculi. One of three cross-reactive antibodies (T84.1) binds to products of each of the three CEAgene families described so far e.g. CEA, the nonspecific cross-reacting antigen, and the biliary glyco-p roteinl (6, 8, 14) . Monoclonal antibody T84.l binds CEA with high affiiiity (10, 22) . The anti-CEA monoclonal antibodies, which show no significant erossreactivity with granulocytes and bile canaliculi, sh w a distinct antigen specificity. in addition to binding to CEA, monoclonal antibody CEA. 11 binds to a the M r of CEA low (125000) described by Hammertumour-associated antigen with an-M r of 128000 ström and co-workers (l 5). Structural studies suggest (CRA-128). Monoclonal antibody T84.66 does not a close relationship to CEA (J. Shively, personal comcross-react with CRA-128 (14) . Monoclonal antibod-muriicätion). Since CRA-128 does not bind monoies with binding properties similar to monoclonal an-clonal antibodies against the non-specific cross-reacttibody CEA. 11 have been described by Suzuki et al. ing antigen (unpublished observation), it is different (16) and Schwarz et al. (17) . from antigens related to the non-specific cross-reacting antigen. According to Barnett et al. (7), the M T of The relationship ofCRA-128 to the different products CRA-128 would be eompatible with the product of of the CEA gene family has not been established. The the unspliced transcript of the biliary glycoprotein I relative molecular mass of the antigen is similar to gene published recently (6 According to recent Western blot studies, CRA-128 was found in 6/9 malignant tissues or effusions (unpublished observation). Furthermore, Suzuki et al. (16) provided evidence that a related antigen is present in serum samples from patients with malignant disease. These data indicate that the determination of CRA-128 in serum may be of value in tumour diagnosis.
In order to answer the question of whether CRA-128 may appear in the blood of tumour patients, two different additive solid phase immunöassays were established. In both assays, the broadly cross-reactive monoclonal antibody T84.1 was immobilized on a solid support. Either monoclonal antibody T84.66 or monoclonal antibody CEA. 11 was used äs the second antibody. The specificities of these immunöassays were analysed by the use of tumour extracts, in which both CEA and CRA-128 had been shown to be present by Western blots. After immunoadsorption of the extracts to a T84.66 immunosorbent, no residual CEA activity could be detected in the T84.66 immunoassay. In contrast, residual antigen binding was demonstrated by the CEA. 11 immunoassay. These data show that the CEA. 11 immunoassay detects an antigen which does not interfere in the T84.66 assay.
Like other investigators (23 -26) we found that antimouse IgG activity in sera of normal persons and tumour patients can give rise to falsely elevated antigen concentrations. In the T84.66 immunoassay, in which antigen and antibodies are incubated for l h, the unspecific interferences coüld be blocked by the addition of 10 ml/l mouse serum. Because of the longer incubation time of the CEA. 11 assay (17h), this assay was mofe sensitive to interference by antim ouse IgG binding substances of low affmity, which could not be eliminated by the addition of normal mouse IgG even at high concentration. The unspecific binding effects were eliminated by the use of F(ab) 2 -fragments of monoclonal antibody T84.1 on the solid phase.
Serum samples from patients with malignant and nonmalignant disease, äs well äs from apparently healthy persons, were analysed by the above immunöassays äs well äs by two commercial assays. The correlation between the T84.66 assay and the commercial assays was comparable with the correlation between the commercial assays. A poorer correlation was observed between the CEA. 11 assay and the remaining assays. This finding may be related either to the distinct antigen specificity of the CEA. 11 assay or to its higher variance. The higher variance of the CEA. 11 assay is probably due to the lower affinity of monoclonal antibody CEA. 11 in comparison with monoclonal antibody T84.66 (10) .
The distributions of CEA concentrations in sera of patients with colorectal cancer vs. non^malignaet gastrointestinal and liver disease were (Jiscriminated by the CEA. 11 assay at a higher level of significance than by the T84.66 assay (flg. 6). Höwever, a direct comparison of the CEA concentrations determined by the CEA. 11 and T84.66 immunöassays by Wilcoxon's matched pairs signed rank test revealed no significant differences in patients with colorectal cancer or in patients with benign gastrointestinal and liver disease. In the diagnosis of mammary and lung cancer, the CEA. 11 immunoassay yielded significantly lower CEA concentrations than the T84.66 assay. The diagnostic value of the CEA. 11 assay is further limited by the finding that significantly higher CEA values were observed in several non-malignant conditions, notably in patients with non-malignant kidney disease, including a significant number of patients with chronic renal failure. It has been reported that the rate of false positives in chronic renal failure differs considerably in different CEA immunoassays. This finding may be explained by the epitope specificities of the antibodies.
The results reported here indicate that CRA-128, a CEA related tumour-associated antigen with a relative molecular mass of 128000, is not significantly elevated in the sera of patients with malignant disease. Suzuki et al. (16) described an immunoassay with an antigen specificity similar to the CEA. 11 assay. In three serum specimens from tumour patients, significantly elevated antigen concentrations remained after adsorption to a CEA-specific immunosorbent. No Information on the relative frequency of such serum specimens among sera from tumour patients were given. Though CRA-128 was detected in 6/9 extracts from malignant tissues or effusions in malignant diseases (unpublished observation), the release of CRA-128 into the circulation seems not to be significant. A possible explanation for this finding are the differences between the membrane anchors of CEA-related antigens. CEA is anchored to the cell membrane via phosphatidylinositol (27) (28) (29) . It has been suggested that the cleavage of CEA from the membrane by endogenous phospholipase C may be critical for the release into the blood stream (28) . In contrast to the CEA-gene, the gene coding for biliary glycoprotein I predicts a transmembraneous and a cytoplasmic domain. If the M T 128000 antigen is anchored via the latter mechanism, äs suggested by Barnett et al. (7), it would not be easily released into the circulation.
